Biosimilars Gain Traction, Generate Savings
July 26th 2021The use of oncology biosimilars has expanded rapidly in the United States during the past 2 years as providers embraced a growing armamentarium of new products, according to findings from real-world data reported at the 2021 American Society of Clinical Oncology Annual Meeting.
Read More
Physician Confidence in Biosimilars Rests on Real-world Data
May 19th 2021Providers and health care institutions want more real-world data on how patients respond to various biosimilar products, according to a varied panel of private practice, academic hospital, and group purchasing organization experts in a discussion at the Community Oncology Alliance virtual 2021 Community Oncology Conference in April.
Read More
ASCO Identifies Additional Ways to Improve Hazardous Drug Safety
February 24th 2020The United States Pharmacopeial Convention (USP) General Chapter is a good start for improving the protection of healthcare workers exposed to hazardous drugs, but more studies and safety protocols are needed, according to an American Society of Clinical Oncology (ASCO) expert panel that evaluated USP and various other guidelines in a report last year.
Read More
T-Cell Immunotherapy Pioneer Seeks New Direction for Solid Tumors
January 11th 2020CAR T cells are a highly active field of investigation, with many companies at work on formulations they hope to bring to market, but these agents have limitations, particularly with metastasized solid tumors.
Read More
Pazdur Followed the Pathway of Greatest Resistance to the FDA
December 30th 2019Richard Pazdur, MD, set out to be a leader in medicine and a teacher of doctors. He achieved that and more, turning the oncology drugs section of the FDA from a poorly understood and lead-footed division into a fast-moving and patient-responsive entity.
Read More
Neoadjuvant Approaches Showcase Advantages in NSCLC
November 10th 2019Based on efficacy, tolerability, and practicality, neoadjuvant therapy in lung cancer offers significant advantages over adjuvant treatment, said Jamie E. Chaft, MD, in a presentation during the 14th Annual New York Lung Cancers Symposium®. However, she added, adjuvant treatment predominantly remains the standard of care at many cancer centers, she said.
Read More
CFS® Experts: Novel Therapies and Onco-Genomics Add Heft to Precision Medicine
October 2nd 2019Co-chairs William K. Oh, MD, Adam M. Brufsky, MD, PhD, and Benjamin P. Levy, MD, preview key topics that will be covered at the 37th Annual CFS®: Innovative Cancer Therapy for Tomorrow symposium.
Read More
A Gifted Leader Who Broadened Investigative Work in Oncology
August 3rd 2019A 2018 Giants of Cancer Care award for Community Outreach, Education, and Cancer Policy, Richard L. Schilsky, MD, built a scaffolding upon which new trials were launched into emerging areas of oncology investigation. His work has led to new standards in cancer care, particularly in breast cancer, and along the way he has furthered the careers of many successful and talented oncologists and investigators.
Read More
Large Myeloma Study Aims to Analyze Multiple Regimens
May 6th 2019Therapy for patients with multiple myeloma encompasses many agents and potential combinations, but truly personalizing care will require knowing how those agents interact for maximum efficacy and incorporating patient preferences for toxicity into the care plan.
Read More
Genetic Testing Recommended for All Patients With Pancreatic Cancer
April 12th 2019In a provisional clinical opinion, an expert panel convened by the American Society of Clinical Oncology has recommended that patients with pancreatic cancer undergo assessment of risk for hereditary syndromes that contribute to higher likelihood of pancreatic cancer.
Read More
The Debate Over Early Screening for Pancreatic Cancer Continues
March 8th 2019Higher costs associated with advanced stage pancreatic cancer, are potentially avoidable with screening and earlier treatment. However, the US Preventive Services Task Force in an ongoing draft review has reaffirmed its stance against screening in asymptomatic individuals.
Read More
Making the Case for Earlier CAR T-Cell Therapy in Lymphoma
March 2nd 2019Real-world data on the use of chimeric antigen receptor T-cell therapy in large B-cell lymphoma bear out the pivotal results from ZUMA-1 and demonstrate not only that the treatment approach is here, but also that it’s time to address issues of efficacy, safety, cost, and moving this approach into earlier lines of therapy.
Read More